Asset Details
Do you wish to reserve the book?
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Do you wish to request the book?
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
2011
Overview
In this trial involving patients infected with hepatitis C virus (HCV) genotype 1 in whom previous treatment had failed, boceprevir plus peginterferon and ribavirin was more effective than peginterferon and ribavirin alone. Adverse effects of boceprevir included anemia and neutropenia.
More than 170 million people are chronically infected with hepatitis C virus (HCV) worldwide.
1
The standard treatment is combination therapy with peginterferon and ribavirin.
2
–
4
Of the six HCV genotypes, genotype 1 is the least responsive to currently approved therapies, with rates of sustained virologic response of less than 50%.
2
,
5
–
7
Thus, there is a large population of patients with few therapeutic options, and direct-acting antiviral therapy has become the focus of investigations regarding treatment for HCV infection.
8
–
11
Boceprevir is a structurally novel peptidomimetic ketoamide protease inhibitor that binds reversibly to the HCV nonstructural 3 (NS3) active site. . . .
Publisher
Massachusetts Medical Society
Subject
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiviral Agents - adverse effects
/ Antiviral Agents - therapeutic use
/ Biological and medical sciences
/ Female
/ Genotype
/ Hepacivirus - isolation & purification
/ Hepatitis C, Chronic - drug therapy
/ Hepatitis C, Chronic - virology
/ HIV
/ Human immunodeficiency virus
/ Humans
/ Interferon-alpha - therapeutic use
/ Male
/ Pharmacology. Drug treatments
/ Polyethylene Glycols - therapeutic use
/ Proline - analogs & derivatives
/ Serine Proteinase Inhibitors - adverse effects
We currently cannot retrieve any items related to this title. Kindly check back at a later time.